Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Mar
16
Today In Oncology
Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males
p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors
BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma
Disease Stage at Breast Cancer Diagnosis Impacted by Region Race and Insurance
Can Viral Respiratory Infections Increase Lung Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo